Altshuler Shaham’s Indaptus Therapeutics INDP Stock Holding History

Altshuler Shaham’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3	Closed	-$27K	–	486
2019 Q2	$27K	Hold	3	–	–	﹤0.01%	195
2019 Q1	$46K	Hold	3	–	–	﹤0.01%	123
2018 Q4	$47K	Sell	3 -27	-90%	-$368K	﹤0.01%	119
2018 Q3	$130K	Buy	30 +1	+3%	+$9.5K	0.01%	108
2018 Q2	$97K	Buy	29 +26	+867%	+$288K	0.01%	106
2018 Q1	$39K	Sell	3 -1	-25%	-$14.2K	0.01%	114
2017 Q4	$35K	Buy	+4	New	+$62K	0.01%	100

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Altshuler Shaham's INDP Position: Q3 2019 in Review

Altshuler Shaham sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 3 shares — an estimated $27K sold.

Altshuler Shaham first reported a position in INDP in Q4 2017 and held it in 7 quarters. The position peaked at $130K in Q3 2018. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

Altshuler Shaham reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
Altshuler Shaham sold 3 Indaptus Therapeutics shares in Q3 2019, an estimated $27K.
Altshuler Shaham first reported a position in Indaptus Therapeutics in Q4 2017 and held it in 7 quarters.
Altshuler Shaham's Indaptus Therapeutics position peaked at $130K in Q3 2018.
33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on Altshuler Shaham's 13F filing for Q3 2019, filed 12 Nov 2019.